Storm Therapeutics is a spin out from the Gurdon Institute in Cambridge, based on the work of Professors Kouzarides and Miska, two world-leading researchers in this breaking field of new target biology.
Prof Tony Kouzarides is a leader in chromatin, epigenetic modifications of chromatin and RNAs and their involvement in cancer. Prof Eric Miska is a leader in the area of non-coding RNA acting in development, physiology and disease, particularly cancer.
RNA is the only direct product of the human genome and acts as the template for the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision making. There are several large families of RNA-modifying enzymes which catalyse a diverse range of epigenetic modifications of RNA, changing RNA activity and therefore key processes within the cell. There is a growing understanding of the importance of RNA modification in the development of cancer, opening up novel therapeutic targets in cancer treatment.
Professors Kouzarides and Miska and their research groups have identified certain of these RNA-modifying enzymes against which Storm Therapeutics intends to develop potential therapeutics.